LEAWOOD, Kan., Oct. 27, 2016 /PRNewswire/ -- Aratana
Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company
focused on the licensing, development and commercialization of
innovative biopharmaceutical products for companion animals, plans
to present at the 2016 Credit Suisse Healthcare Conference on
Tuesday, November 8 at 8:30 a.m. MT in Scottsdale, Arizona and at Stifel Healthcare
Conference 2016 on Wednesday, November
16 at 8:45 a.m. ET in
New York City.
Both the Credit Suisse Healthcare Conference and the Stifel
Healthcare Conference presentations will be webcast and interested
parties may listen live or access the audio link for up to 90 days
after the meeting. Presentation slides from the conference will
also be available in the Aratana Investor Room.
About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on
licensing, developing and commercializing innovative
biopharmaceutical products for dogs and cats. Aratana believes that
it can leverage the investment in the human pharmaceutical industry
to bring therapeutics to pets in a capital and time efficient
manner. The Company has multiple products approved by the Food and
Drug Administration's Center for Veterinary Medicine or licensed by
the United States Department of Agriculture. The Company's pipeline
includes therapeutic candidates targeting pain, inappetence,
cancer, viral diseases, allergy and other serious, unmet or
underserved medical needs. Aratana believes providing
innovative options to veterinarians and pet owners will help manage
pets' medical needs safely and effectively, result in longer and
improved quality of life for pets. For more information, please
visit www.aratana.com.
Contacts
For investor inquires:
Craig
Tooman
ctooman@aratana.com
(913) 353-1026
For media inquiries:
Rachel
Reiff
rreiff@aratana.com
(913) 353-1050
Logo - http://photos.prnewswire.com/prnh/20160425/359503LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/aratana-therapeutics-to-present-at-two-upcoming-investor-conferences-300353034.html
SOURCE Aratana Therapeutics, Inc.